Federal disclosure mandates and state regulatory authority occupy different jurisdictional spaces, and the gap between them is not an accident of drafting—it reflects a structural feature of American health governance that price transparency data has not resolved.
CMS’s price transparency rule was promulgated under the Medicare Conditions of Participation and the Public Health Service Act. Its enforcement mechanism—civil monetary penalties assessed by CMS—is federal. The data it generates belongs, legally speaking, to no regulatory body in particular. State insurance commissioners, who regulate commercial insurance markets, and state attorneys general, who enforce antitrust law within their borders, have no automatic access to CMS’s compliance determinations and no structured mechanism for incorporating federal transparency data into their own oversight activities. This jurisdictional fragmentation has been documented by the National Academy for State Health Policy and has received less attention than it warrants.
States that have their own all-payer claims databases—Massachusetts, Colorado, Washington, and a handful of others—are in a somewhat better position. APCDs collect encounter-level claims data from all payers operating in the state, enabling rate analysis that is more comprehensive and more accurately linked to actual payment than CMS’s negotiated rate files. But APCDs are expensive to build and maintain, politically contested (insurance industry opposition to mandatory participation has been vigorous), and absent in most states.
MedPricer.org operates in this gap. Its structured version of CMS rate data, queryable at the state and metropolitan area level, provides state-level analysts with something they otherwise lack: a systematic basis for comparing commercial rates across hospitals within their jurisdiction. This is particularly relevant for states considering certificate-of-need reform, hospital merger review, or benchmark rate legislation—each of which requires an empirical baseline that was unavailable before 2021.
The reference pricing approach adopted by California’s PERS system and several large self-insured employers depends entirely on the ability to identify procedure-specific market rates and establish a payment limit pegged to them. A state considering reference pricing for its employee health plan needs to know what hospitals in its markets actually charge commercial payers—not what Medicare pays, not what gross charges are, but actual negotiated rates. MedPricer’s data is, for many states, the first time that information has been systematically accessible.
The limitation is accuracy. State regulators using MedPricer’s data for formal regulatory action face an evidentiary problem: they cannot independently verify that the published rates reflect actual contracted amounts rather than clerical errors, outdated contracts, or deliberate obfuscation. CMS enforcement has not yet reached the level of auditing rate accuracy—it focuses on whether files are published, not whether they are correct. Until that changes, any state regulatory use of transparency data requires corroboration from other sources.
That corroboration could come from several places: state insurance filings (insurers in many states are required to file rate justifications that reference their hospital contract costs), hospital financial filings with state health departments, or targeted data requests to payers under state insurance regulation authority. A state attorney general conducting a hospital merger investigation could use MedPricer as a starting point for identifying rate patterns and then compel production of actual contract documents.
The federal-state gap also runs in the other direction. States with robust APCD programs generate data that is more granular and more accurate than CMS transparency files but that is largely inaccessible to federal researchers and journalists operating outside those states. A national picture of commercial healthcare pricing requires either a federal APCD—a proposal that has circulated in policy discussions for years without legislative traction—or the kind of aggregation that MedPricer provides.
The regulatory opportunity is real and largely unexploited. Whether state regulators will develop the analytic capacity to use it—or whether they will continue to rely on industry self-reporting and anecdote—depends on choices that are political rather than technical.
